ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1586

Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing

Zachary Peters1, Lindsay Mendyka2, Sicong Shan1, William Rigby3, Christopher Burns4, Randolph Noelle5 and Sladjana Skopelja-Gardner4, 1Dartmouth College, Hanover, NH, 2Dartmouth Hitchcock, Lebanon, NH, 3Dartmouth-Hitchcock, Norwich, VT, 4Dartmouth Hitchcock Medical Center, Lebanon, NH, 5Geisel School of Medicine at Dartmouth, Hanover, NH

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, immunology, interferon, skin, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Innate Immunity

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We previously showed IFN-I induction by UV occurs in a cGAS-STING-dependent manner, but the IFN-I signature returns to baseline levels in healthy skin, unlike in lupus. Here, we propose that the immune checkpoint VISTA is a regulator of skin IFN-I production in keratinocytes of therapeutic relevance to lupus.

Methods: Skin biopsies from B6, B6.Vsir-/- (VISTA-deficient), B6.Vsir-/-Sting-/-, KRT14creVsirfl/fl (Vsir-/- in keratinocytes), and cre-Vsirfl/fl female mice (3 mo) were collected prior to, 3 and 24h after UVB (500mJ/cm2). Gene expression was quantified by RNA-seq (Rosalind). Skin infiltrating cells were quantified by flow cytometry. Human keratinocytes were isolated from healthy skin and cultured in vitro. Cells were treated with agonistic anti-VISTA (803) or isotype IgG2a (20ug/ml) prior to UVB (50mJ/cm2), in the presence or absence of IFNa (100U). Expression of IFN-Is and IFN-I stimulated genes (ISGs) were quantified by qPCR (4hr after UV) and IFN-I score derived.

Results: At baseline, B6.Vsir-/- skin had increased IFN-k mRNA, IFN-b protein, as well as total STING protein levels (Fig. 1A-C). RNA-seq revealed increased expression of Sting and upstream cytosolic DNA sensors in VISTA-deficient mouse skin before and after UV. B6.Vsir-/- mice exhibited a 5-fold higher skin IFN-I score after UV compared to B6 mice (Fig.1D). Higher baseline and UV-induced IFN-I response in VISTA-deficient skin was suppressed in the absence of STING (Vsir-/-Sting-/- mice). Moreover, fewer skin-infiltrating neutrophils and inflammatory monocytes were recruited to Vsir-/-Sting-/- vs. STING-sufficient Vsir-/- skin post UV. RNAseq also revealed decreased expression of DNA repair genes like Ogg1, Xpd and Pole in B6.Vsir-/- skin, which are essential for repair of UV-induced DNA damage. VISTA deficient mouse keratinocytes produced 2-fold higher IFN-k at baseline ex vivo and accumulated higher levels of oxidized DNA (8-OHdG) compared with B6 cells (Fig. 2B-C).Mice with a conditional VISTA deletion only in keratinocytes exhibited a 10-fold higher baseline IFN-I signature and increased IFN-b protein levels compared to controls (Fig. 2D-E). Expression of VISTA on human keratinocytes decreased 4 hr after UV, but increased 5-fold 24 hr after UV(Fig. 3A).Pre-treatment of human keratinocytes with an agonistic anti-VISTA antibody (803) suppressed UV-induced IFN-k, Stat1 phosphorylation and IFN-I score, even in keratinocytes with a pre-existing IFN-I signature (Fig. 3C-D).

Conclusion: These studies identify VISTA as a suppressor of IFN-I production in keratinocytes and demonstrate STING-dependent IFN-I production in the absence of VISTA. As oxidized DNA is resistant to degradation in the cytosol where it can serve as a potent trigger of cGAS-STING, VISTA promotion of DNA repair may indirectly suppress STING signals. Antibody-mediated activation of VISTA in keratinocytes demonstrates its potential as a target to suppress IFN-I production in the context of photosensitivity and lupus.

Supporting image 1

Figure 1. Elevated skin IFN-I production in the absence of VISTA. A. IFN-β immunoblot of B6 and B6.Vsir-/- skin lysates; levels normalized to β-actin (ImageJ). B. IFN-k gene expression in B6 and Vsir-/- whole skin measured by qPCR. C. STING immunoblot of B6 and B6.vsir-/- skin lysates. D. Skin IFN score in B6 and Vsir-/- mice, before and after UVB exposure (1x500mJ/cm2). Differences in gene expression determined relative to baseline B6 and all statistical significance determined by two-way ANOVA (A,D) or Student’s T test(B,C) (n=5, *p<0.05, **p<0.01, ***p<0.005, ****p<0.00001). IFN-I score calculated as sum normalized expression of 6 ISGs relative to baseline B6 (ISGs: IRF7, IFIT1, IFIT3, ISG15, IFI27La, Mx1) and normalized to 18s.

Supporting image 2

Figure 2. VISTA regulates IFN-I production in keratinocytes. A. Mouse epidermis stained for VISTA (red), Keratin_14 (green), and DAPI (blue). B. Baseline IFN-κ protein in B6 and Vsir-/- keratinocyte lysates after 6 days in culture, quantified relative to B-actin. C. Mouse keratinocytes stained for 8-hydroxyguanosine (yellow) and DAPI (blue). D. IFN-b immunoblot of skin lysates from B6, B6.Vsir-/-, Vsirfl/fl and KRT14Cre:Vsirfl/fl mice. E. Baseline skin IFN-I score of Vsirfl/fl and KRT14Cre:Vsirfl/fl mice. Significance determined by two-way ANOVA (A). (n=3, * p<0.05, p<0.01). Differences in gene expression relative to Vsirfl/fl control and statistical significance determined by T test (n=4).

Supporting image 3

Figure 3. Anti-VISTA agonistic IgG suppresses UV-induced IFN-I signature in human keratinocytes. A. VISTA surface expression on primary human keratinocytes measured by flow cytometry, without UV, 4 and 24hr after UVB (50mJ/cm2). B. IFN-k gene expression in human keratinocytes pre-treated with either anti-VISTA INX803 IgG2 or isotype control IgG2 antibody. C. IFN-I scores of human keratinocytes pre-treated with 803 or isotype control IgG2 before and after UV exposure were derived as the sum of normalized expression levels of 9 interferon-stimulated genes (CXCL10, BST2, ifitm3, ifi27, isg15, ifit1, mx1, Ly6E, irf7). D. Immunoblot of phosphorylated STAT1 and IFN-k in human keratinocyte lysates from cells before and after UVB exposure, in the absence or presence of IFN⍺ (100U, 24hr prior to UV exposure) and pre-treated with anti-VISTA 803 or isotype control IgG2 antibody. Pixel intensity calculated relative to b-actin (ImageJ) and fold change of P-STAT1 and IFN-k in the presence of IFNa calculated relative to baseline NoUV. Statistical significance was determined by two-way ANOVA(A,C) and Student’s t-test (B,D); *p<0.05, **p<0.01, ns= not significant.


Disclosures: Z. Peters: None; L. Mendyka: None; S. Shan: None; W. Rigby: None; C. Burns: None; R. Noelle: None; S. Skopelja-Gardner: None.

To cite this abstract in AMA style:

Peters Z, Mendyka L, Shan S, Rigby W, Burns C, Noelle R, Skopelja-Gardner S. Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/keratinocyte-vista-suppresses-skin-ifn-i-production-by-regulating-dna-damage-repair-and-cytosolic-dna-sensing/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/keratinocyte-vista-suppresses-skin-ifn-i-production-by-regulating-dna-damage-repair-and-cytosolic-dna-sensing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology